Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10 Results for "
covalent dimerization
" in MedChemExpress (MCE) Product Catalog:
Products (10)
10 Results for "covalent dimerization" in MCE Product Catalog:
4
4 Cited Publications
Target:
Research Areas:
BS3 Crosslinker is a cell-impermeable NHS ester crosslinker. BS3 Crosslinker "covalently locks" two spatially adjacent proteins on the surface of living cells into a covalent complex, and the dimerization/oligomerization status is determined by observing molecular weight shifts via Western blot. BS3 Crosslinker can crosslink EGFR and c-MET to assist in detecting and evaluating their dimerization status. It can be used in research related to oral cancer and glioblastoma .
4
4 Cited Publications
Target:
Research Areas:
BS3 Crosslinker disodium is a cell-impermeable NHS ester crosslinker. BS3 Crosslinker disodium "covalently locks" two spatially adjacent proteins on the surface of living cells into a covalent complex, and the dimerization/oligomerization status is determined by observing molecular weight shifts via Western blot. BS3 Crosslinker disodium can crosslink EGFR and c-MET to assist in detecting and evaluating their dimerization status. It can be used in research related to oral cancer and glioblastoma .
2
2 Cited Publications
Target:
Research Areas:
HaXS8 is a dimerizer that can promote a covalent and irreversible intracellular dimerization of HaloTag and SNAP-tagged proteins of interest. HaXS8 does not interfere with PI3K/mTOR signaling .
1
1 Cited Publications
Cat. No.: HY-124700
CAS No.: 1966129-74-7
Research Areas:
LYPLAL1-IN-1 (compound 11) is a selective, covalent, and irreversible inhibitor of the lysophospholipase-like enzyme LYPLAL1 (IC50 = 6 nM). LYPLAL1-IN-1 shows selectivity against other serine hydrolases such as carboxylesterase CES1 (IC50 > 50 μM for CES1). LYPLAL1-IN-1 inhibits the depalmitoylation function of LYPLAL1, blocking its depalmitoylation modification of cyclic GMP-AMP synthase (cGAS), thereby promoting cGAS dimerization and activation, and initiating the cGAS-STING pathway-mediated innate immune response. LYPLAL1-IN-1 can enhance DNA-induced type I interferon production, upregulate PD-L1 expression in tumor cells, and promote the accumulation of tumor-infiltrating CD8 + T cells, with the core function of strengthening the anti-tumor immune response. LYPLAL1-IN-1 is primarily used in tumor immunology research, especially in combination with PD-1/PD-L1 inhibitors .
Cat. No.: HY-P3223A
Target:
Research Areas:
Cat. No.: HY-P3223
CAS No.: 126872-95-5
Target:
Research Areas:
Cat. No.: HY-D2935
CAS No.: 680622-88-2
Cat. No.: HY-D2995
CAS No.: 945966-30-3
Cat. No.: HY-D2981
CAS No.: 680622-77-9
Cat. No.: HY-124329AS
CAS No.: 910292-87-4
Research Areas:
BS3 Crosslinker-d4 disodium is the deuterated-labeled BS3 Crosslinker disodium (HY-124329A). BS3 Crosslinker disodium is a cell-impermeable NHS ester crosslinker. BS3 Crosslinker disodium "covalently locks" two spatially adjacent proteins on the surface of living cells into a covalent complex, and the dimerization/oligomerization status is determined by observing molecular weight shifts via Western blot. BS3 Crosslinker disodium can crosslink EGFR and c-MET to assist in detecting and evaluating their dimerization status. It can be used in research related to oral cancer and glioblastoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
